Per Sonne Holm

3.2k citations

92 papers · 2.3k indexed · h-index 30

Co-authors: Hermann Lage Klaus Mantwill Bernd Gänsbacher Roman Nawroth Flemming Reymann J. K. Larsen C. Peterson Olof Larsson
Topics: Virus-based gene therapy research (33 papers)RNA Interference and Gene Delivery (18 papers)CAR-T cell therapy research (18 papers)
Cited by: Microbiology Genetics Oncology
Journals: Nucleic Acids Research Journal of Biological Chemistry Nature Communications
Partner nations: Germany Denmark Austria

In The Last Decade

Per Sonne Holm

89 papers receiving 2.2k citations

Peers

Countries citing papers authored by Per Sonne Holm

Since Specialization

Citations

This map shows the geographic impact of Per Sonne Holm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Sonne Holm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Sonne Holm more than expected).

Fields of papers citing papers by Per Sonne Holm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Sonne Holm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Sonne Holm. The network helps show where Per Sonne Holm may publish in the future.

Co-authorship network of co-authors of Per Sonne Holm

This figure shows the co-authorship network connecting the top 25 collaborators of Per Sonne Holm. A scholar is included among the top collaborators of Per Sonne Holm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Sonne Holm. Per Sonne Holm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gout: An Overlooked Disease in Patients With Diabetes? A Danish Prospective Cohort Study With 2 Years of Follow-Up 2025 ·Clinical Diabetes ·Claus Rasmussen,(unknown),Per Sonne Holm,Gunnar Lauge Nielsen	0
2	Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer 2025 ·Scientific Reports ·(unknown),(unknown),Klaus Mantwill,Per Sonne Holm,Kristina Schwamborn,Danny Jonigk,Jürgen E. Gschwend,Michael Rose,Nadine T. Gaisa,Roman Nawroth	1
3	TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model 2024 ·Frontiers in Immunology ·Sebastian Johannes Schober,Melanie Thiede,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Julia Hauer,Stefan Burdach,Per Sonne Holm,Uwe Thiel	3
4	Development of an optimized, non‐stem cell line for intranasal delivery of therapeutic cargo to the central nervous system 2023 ·Molecular Oncology ·(unknown),Arsen Arakelyan,(unknown),(unknown),(unknown),Irene González-Menéndez,(unknown),Per Sonne Holm,Wolfgang Mikulits,Matthias Schwab,Lusine Danielyan,Ulrike Naumann	2
5	The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma 2023 ·Clinical Cancer Research ·Sebastian Johannes Schober,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Melanie Thiede,Julia Hauer,Andreas Kolk,Klaus Mantwill,Jürgen E. Gschwend,Stefan Burdach,Roman Nawroth,Uwe Thiel,Per Sonne Holm	14
6	Intranasal Delivery of Oncolytic Adenovirus XVir-N-31 via Optimized Shuttle Cells Significantly Extends Survival of Glioblastoma-Bearing Mice 2023 ·Cancers ·(unknown),(unknown),(unknown),(unknown),Per Sonne Holm,Lusine Danielyan,Ulrike Naumann	5
7	Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer 2019 ·Journal of Experimental & Clinical Cancer Research ·Zhichao Tong,Anuja Sathe,(unknown),Qi Pan,Christian Veltkamp,Juergen E. Gschwend,Per Sonne Holm,Roman Nawroth	27
8	The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer 2018 ·Human Gene Therapy ·(unknown),Florestan Koll,(unknown),Klaus Mantwill,Klaus‐Peter Janssen,Melanie Laschinger,Jürgen E. Gschwend,Katja Steiger,Peter C. Black,Igor Moskalev,Roman Nawroth,Per Sonne Holm	18
9	Virotherapy Research in Germany: From Engineering to Translation 2017 ·Human Gene Therapy ·Guy Ungerechts,Christine E. Engeland,Christian J. Buchholz,Jürgen Eberle,Henry Fechner,Karsten Geletneky,Per Sonne Holm,Florian Kreppel,Florian Kühnel,Karl S. Lang,Mathias F. Leber,Antonio Marchini,Markus Moehler,Michael D. Mühlebach,Jean Rommelaere,Christoph Springfeld,Ulrich M. Lauer,Dirk M. Nettelbeck	20
10	YB-1-basierte Virotherapie: Ein neues Therapiekonzept beim Urothelkarzinom der Harnblase 2016 ·Urologe A ·Per Sonne Holm,Margitta Retz,(unknown),Roman Nawroth	0
11	An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment 2014 ·Cancer Gene Therapy ·(unknown),Klaus Mantwill,Per Sonne Holm,Martina Anton	14
12	MAPK and PI3K/AKT mediated YB‐1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop 2012 ·Experimental Dermatology ·Tobias Sinnberg,Birgit Sauer,Per Sonne Holm,(unknown),Silke Kuphal,Anja‐Katrin Bosserhoff,Birgit Schittek	57
13	AdVEGF₁₆₅ gene transfer increases survival in overdimensioned skin flaps 2004 ·The Journal of Gene Medicine ·Riccardo E. Giunta,Thomas Holzbach,(unknown),Per Sonne Holm,Moritz A. Konerding,D. Schams,E. Biemer,Bernd Gänsbacher	43
14	YB-1 Relocates to the Nucleus in Adenovirus-infected Cells and Facilitates Viral Replication by Inducing E2 Gene Expression through the E2 Late Promoter 2002 ·Journal of Biological Chemistry ·Per Sonne Holm,Stephan Bergmann,Karsten Jürchott,Hermann Lage,Karsten Brand,Axel Ladhoff,Klaus Mantwill,David T. Curiel,Matthias Dobbelstein,Manfred Dietel,Bernd Gänsbacher,Hans‐Dieter Royer	90
15	Selection of a high activity ribozyme against cytostatic drug resistance-associated glypican-3 using an in vitro assay containing total tumor RNA 1999 ·Cancer Gene Therapy ·(unknown),Per Sonne Holm,Manfred Dietel,Hermann Lage	6
16	Moclobemide and placebo in mild major depression: a double-blind randomized trial 1992 ·Psychopharmacology ·(unknown),Per Sonne Holm	16
17	Moclobemide and clomipramine in reactive depression 1989 ·Acta Psychiatrica Scandinavica ·J. K. Larsen,Per Sonne Holm,Eyd Hansen Høyer,(unknown),(unknown),Anne Vingaard Olesen,(unknown)	24
18	The Treatment of Psoriasis with 0.1% Domoprednate (a <i>D</i>-Homocorticosteroid) and 0.1% Betamethasone Valerate Ointment 1985 ·Dermatology ·(unknown),(unknown),Per Sonne Holm,(unknown),Flemming Reymann	2
19	Patients’ Acceptance of Etretinate Therapy 1984 ·Dermatology ·(unknown),Per Sonne Holm,Flemming Reymann,Kristian Thestrup‐Pedersen	6
20	A Randomized Trial of Etretinate (Tigason®) in Palmoplantar Pustulosis 1983 ·Dermatology ·(unknown),Per Sonne Holm,(unknown),Grete Laurberg,Flemming Reymann,(unknown),Susanne Ullman	26

About Per Sonne Holm

Per Sonne Holm is a scholar working on Microbiology, Genetics and Oncology, having authored 92 papers that have together received 2.3k indexed citations. Recurring topics across this work include Virus-based gene therapy research (33 papers), RNA Interference and Gene Delivery (18 papers) and CAR-T cell therapy research (18 papers). The work is most often cited by research in Microbiology (67 citations), Genetics (657 citations) and Oncology (626 citations). Per Sonne Holm has collaborated with scholars based in Germany, Denmark and Austria. Frequent co-authors include Hermann Lage, Klaus Mantwill, Bernd Gänsbacher, Roman Nawroth, Flemming Reymann, J. K. Larsen, C. Peterson, Olof Larsson, Sigurd Vitols and B Aberg. Their work appears in journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact